{"preliminary_commentary":{"by_channel":{"x_thread":25,"youtube":17,"podcast":16},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03051464\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"stage II–III rectal cancer","name":"MORPHEUS","nct_id":"NCT03051464","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=morpheus-nct03051464. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MORPHEUS","arms":[{"description":"standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders","label":"Chemoradiation + EBRT Boost","type":"EXPERIMENTAL"},{"description":"standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders","label":"Chemoradiation + HDRBT Boost","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-01","type":"ESTIMATED"},"conditions":["Stage II Rectal Cancer","Organ Preservation","Non-operative Treatment","Rectal Cancer (Stage III)","Rectal Cancer Patients"],"enrollment":{"count":131,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Complete responders and Non-complete responders","otherNames":[],"type":"PROCEDURE"},{"name":"Chemoradiation + EBRT Boost","otherNames":[],"type":"RADIATION"},{"name":"Chemoradiation + HDRBT Boost","otherNames":[],"type":"RADIATION"}],"last_update":"2026-06-30","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","official_title":"A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"TME-free survival","timeFrame":"2 years post treatment"}],"references":[],"start_date":{"date":"2017-04-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","url":"https://clinicaltrials.gov/study/NCT03051464"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/morpheus-nct03051464"}